Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can tailored hepatitis c drugs cure infection in kidney patients?

NCT ID NCT07770984

Disease control Sponsor: Tanta University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 18, 2026 · Last updated Aug 21, 2026 · Updated 3 times

Summary

This clinical trial aims to find the safest and most effective hepatitis C treatment for people with chronic kidney disease (CKD). Researchers will compare two drug combinations based on how well the kidneys are working: one for patients with moderate kidney function and another for those with severe impairment or on dialysis. The study will measure whether the virus is eliminated 12 weeks after treatment ends and will monitor liver and kidney health, along with quality of life, to ensure the therapy is both effective and safe.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Sofosbuvir and Daclatasvir, or Paritaprevir/Ombitasvir/Ritonavir with Ribavirin
What this could lead to
If successful, this could identify the best hepatitis C treatment for people with chronic kidney disease, potentially curing their infection and improving kidney and overall health.
What could go wrong
This is a mid-stage trial with a small number of participants, so results may not apply to everyone. The drugs may cause side effects or interact with kidney function, and the cure rate may be lower than hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Both male and female. 2. Adults more than 18 years. 3. Patients with CKD different stages stable on treatment with or without HD. 4. HD Patients should be stable for at least 6 months under regular hemodialysis. 5. Clinically stable condition as outpatients. 6. Patients with HCV infections (serum positive for HCV GT4 with HCV RNA\>1000 IU/ml by PCR). 7. White blood cells count more than 2500/mm3. 8. Platelet count more than 7500/mm3. Exclusion Criteria: 1. Confirmed pregnancy. 2. HCV-HIV co infection. 3. HBV-HCV co infection. 4. Unstable CKD patients. 5. Patients who are recently stabilized on HD (less than 6 months). 6. Patients on peritoneal dialysis. 7. For patients without cirrhosis, Patients will be excluded if ALT or AST more than five times the upper limit of normal. 8. For patients with cirrhosis, Patients will be excluded if ALT or AST are higher than seven times the upper limit of normal.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic kidney disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic kidney disease hepatitis C virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HCV infection ( genotype 4) in CKD patients

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Tanta University, Internal Medicine Department, Nephrology and Dialysis Unite and Viral Committee

    Tanta, Gharbia Governorate, 31719, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.